Toxicities and salvage therapy following overdose of vinblastine in a cat

Grant, Iain; Karnik, K.; Jandrey, Karl E.

doi:10.1111/j.1748-5827.2009.00864.x

Cited by 11 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vinblastine is another vinca alkaloid that is associated with less gastrointestinal and neurotoxicity but more myelosuppression in humans . Several case reports describe the use of vinblastine in cats, but side‐by‐side or randomized comparison of vincristine and vinblastine has not been performed …”

Section: Introductionmentioning

confidence: 99%

“…13 Several case reports describe the use of vinblastine in cats, but side-by-side or randomized comparison of vincristine and vinblastine has not been performed. [14][15][16][17] The purpose of our study was to compare the response rate, progression-free survival (PFS), lymphoma-specific survival (LSS), and gastrointestinal and hematopoietic toxicity between cats that received vincristine as compared with vinblastine as part of a COP-based chemotherapy protocol. We hypothesized that cats in both arms would have similar response rates and outcome and that cats that received vinblastine would have less gastrointestinal toxicity compared with cats that received vincristine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective Clinical Trial to Compare Vincristine and Vinblastine in aCOP‐Based Protocol for Lymphoma in Cats

Krick

Cohen

Gregor

et al. 2012

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Current standard chemotherapy protocols for lymphoma in cats carry risks of gastrointestinal toxicity, which can decrease quality of life and complicate response assessment. Protocols with less gastrointestinal toxicity may improve treatment tolerance.Hypothesis/Objectives: The study purpose was to compare response rate, outcome, and toxicity between cats that received vincristine or vinblastine as part of combination chemotherapy for lymphoma. We hypothesized that vinblastine would have similar efficacy, but less gastrointestinal toxicity, compared with vincristine.Animals: Forty client-owned cats with confirmed diagnosis of lymphoma. Methods: Cats were randomized to 1 of 2 treatment arms and received weekly COP-based chemotherapy for 6 months or until disease progression. Response rate, progression-free survival (PFS), lymphoma-specific survival (LSS), and incidence and severity of gastrointestinal and hematologic toxicity were compared between arms. Arm cross-over occurred if specific gastrointestinal toxicity criteria were noted.Results: Cats in both arms had similar response rates, PFS, and LSS (48 versus 64 days, P = .87; 139 versus 136 days, P = .96). Cats that received vincristine were significantly more likely to switch arms based on gastrointestinal toxicity than cats that received vinblastine (44.4 versus 10.5%, P = .02). Lower baseline weight was significantly negatively associated with PFS and LSS (P = .01, P = .003, respectively). Baseline anemia was significantly negatively associated with LSS (P = .04).Conclusions and Clinical Importance: Results suggest that vinblastine is a reasonable alternative to vincristine in the treatment of some cats with lymphoma. Baseline body weight remains a significant prognostic factor for cats with lymphoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prospective Clinical Trial to Compare Vincristine and Vinblastine in aCOP‐Based Protocol for Lymphoma in Cats

Krick

Cohen

Gregor

et al. 2012

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…In dogs, SIADH has been seen with hydrocephalus, amoebic meningoencephalitis, heartworm disease, hypothalamic meningeal sarcoma, and idiopathic etiologies . SIADH has been reported in 2 cats, one with liver disease and one subsequent to vinblastine overdose …”

Section: Dysregulation Of Aqp2 In Diseasementioning

confidence: 99%

Aquaporin‐2 regulation in health and disease

Radin

Stoedkilde

et al. 2012

Veterinary Clinical Pathol

View full text Add to dashboard Cite

Aquaporin-2 (AQP2), the vasopressin-regulated water channel of the renal collecting duct, is dysregulated in numerous water balance disorders in humans and animals including those associated with polyuria (e.g. urinary tract obstruction, hypokalemia, inflammation, and lithium toxicity) and dilutional hyponatremia (e.g. SIADH). Normal regulation of AQP2 by vasopressin involves two independent regulatory mechanisms: 1) short-term regulation of AQP2 trafficking to and from the apical plasma membrane, and 2) long term regulation of the total abundance of the AQP2 protein in the cells. Most water balance disorders are the result of dysregulation of processes that regulate the total abundance of AQP2 in collecting duct cells. In general, the level of AQP2 in a collecting duct cell is determined by a balance between production via translation of AQP2 mRNA and removal via degradation and/or secretion into the urine in exosomes. AQP2 abundance increases in response to vasopressin chiefly due to increased translation subsequent to increases in AQP2 mRNA. Vasopressin-mediated regulation AQP2 gene transcription is poorly understood, although several transcription factor binding elements in the 5’ flanking region of the AQP2 gene have been identified and candidate transcription factors corresponding to these element have been discovered in proteomics studies. Here we review progress in this area and discuss elements of vasopressin signaling in the collecting duct that may impinge on regulation of AQP2 in health and in the context of examples of polyuric diseases.

show abstract

“…(4)(5)(6) A VBL overdose (25 mg/m 2 ) was administered in a child with metastatic primitive neuroectodermal tumor. Patient developed acute neurological toxicity and fever.…”

mentioning

confidence: 99%

Overdose of Vinblastine in place of Vinorelbine during IGEV chemotherapy

Aversa

Zanon

Marino

et al. 2012

Immunopharmacology and Immunotoxicology

View full text Add to dashboard Cite

Any class of drugs is susceptible to errors, in case of antineoplastic agents the medication errors may cause severe and life-threatening toxicity due to very limited therapeutic index with toxic events even at therapeutic dosage, to complexity of regimens and the particular vulnerable population. We report herein a case of Vinblastine (VBL) accidental overdose, the cause of mistake, the toxic effect and the salvage therapy adopted in a young lady suffering of Hodgkin relapse during IGEV chemotherapy.

show abstract

Toxicities and salvage therapy following overdose of vinblastine in a cat

Cited by 11 publications

References 24 publications

Prospective Clinical Trial to Compare Vincristine and Vinblastine in aCOP‐Based Protocol for Lymphoma in Cats

Prospective Clinical Trial to Compare Vincristine and Vinblastine in aCOP‐Based Protocol for Lymphoma in Cats

Aquaporin‐2 regulation in health and disease

Overdose of Vinblastine in place of Vinorelbine during IGEV chemotherapy

Contact Info

Product

Resources

About